Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Podobne knjige/članki

• Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
  od: Ida, Motoko, et al.
  Izdano: (2017)
• Ramosetron in Irritable Bowel Syndrome with Diarrhea: New hope or the same old story?
  od: Grover, Madhusudan, et al.
  Izdano: (2014)
• The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
  od: Min, Yang Won, et al.
  Izdano: (2015)
• Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
  od: Chiba, Toshimi, et al.
  Izdano: (2013)
• Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey
  od: Masanori Kosako, et al.
  Izdano: (2018-12-01)